Grade: Pharmaceutical Grade
Factory Location: Quanzhou
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: L/C
On September 20, 2019, the FDA officially approved the marketing application of semaglutide for improving blood sugar control in patients with type 2 diabetes in combination with diet and exercise. Semaglutide is a human GLP-1 analogue with high albumin affinity and a long half-life, enabling once-weekly administration to stimulate insulin secretion and inhibit glucagon secretion in a blood sugar-dependent manner.